Cyclin-dependent kinase inhibitor 1C (CDKN1C) is a key Background: negative regulator of cell growth encoded by a paternally imprinted/maternally expressed gene in humans. Loss-of-function variants in are associated with an overgrowth condition CDKN1C (Beckwith-Wiedemann Syndrome) whereas "gain-of-function" variants in that increase protein stability cause growth restriction as part of CDKN1C IMAGe syndrome ( ntrauterine growth restriction, etaphyseal dysplasia, I M A drenal hypoplasia and nital anomalies). As two families have been Ge reported with mutations who have fetal growth restriction CDKN1C (FGR)/Silver-Russell syndrome (SRS) adrenal insufficiency, we without investigated whether pathogenic variants in could be associated CDKN1C with isolated growth restriction or recurrent loss of pregnancy.
very localised "hot-spot" cause growth restriction, with or without adrenal insufficiency. However, pathogenic variants in this region are not a common cause of isolated fetal growth restriction phenotypes or loss-of-pregnancy/recurrent miscarriages. 
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Introduction
Cyclin-dependent kinase inhibitor 1C (CDKN1C, also known as P57/kip2) (OMIM 600856) is a key negative regulator of cell proliferation that is encoded by a paternally imprinted (maternally expressed) gene on the short arm of chromosome 11 (11p15.4) in humans (Stampone et al., 2018) .
Consistent with its role in growth and development, maternallyinherited loss-of-function variants in CDKN1C are found in approximately 5-10% of individuals with the "overgrowth" condition, Beckwith-Wiedemann Syndrome (BWS) (OMIM 130650) (Eggermann et al., 2014) . Clinical features of BWS include macrosomia, hyperinsulinism and adrenal tumors.
In contrast, gain-of-function variants in CDKN1C have been shown to cause growth restriction as part of IMAGe syndrome (OMIM 614732) (Arboleda et al., 2012) . IMAGe syndrome is characterised by fetal/Intrauterine growth restriction, Metaphyseal dysplasia, Adrenal hypoplasia and Genital anomalies (in males, usually relatively mild hypospadias and undescended testes) as well as additional features such as hearing loss and hypercalciuria (Bennett et al., 1993; Vilain et al., 1999) .
To date, children with IMAGe syndrome have all been found to harbour pathogenic single nucleotide variants (SNVs) in a very specific region of the PCNA-binding domain of CDKN1C (Arboleda et al., 2012; Cabrera-Salcedo et al., 2017) . These changes potentially lead to increased activity through increasing protein stability, thereby preventing cell cycle progression into S phase (Borges et al., 2015; Hamajima et al., 2013) .
More recently, SNVs in the PCNA-binding domain of CDKN1C have been reported in families with maternally-inherited fetal growth restriction (FGR) without adrenal insufficiency and in familial Silver-Russell syndrome (SRS) (OMIM 180860) (Brioude et al., 2013; Kerns et al., 2014) . SRS is characterised by variable clinical features including fetal and post-natal growth restriction, relative macrocephaly, feeding difficulties and characteristic facies. SRS is also described as phenotypically and genotypically opposite to BWS and approximately half of the molecular anomalies are attributed to Chr11p15.5 imprinting clusters, including several individuals with maternal duplication of the locus containing CDKN1C (Bonaldi et al., 2011; Boonen et al., 2016; Schönherr et al., 2007) .
These findings suggest that the growth restriction phenotype associated with CDKN1C may be more variable and adrenal insufficiency is not always present.
The aim of this study was therefore to review published CDKN1C variants associated with FGR/IUGR phenotypes, to study CDKN1C expression in different tissues, and to analyse the critical region in CDKN1C in a range of growth restriction and adverse pregnancy phenotypes, with a hypothesis that severe restriction of feto-placental growth may, in some situations, result in pregnancy loss or recurrent miscarriage.
Methods
Review of pathogenic SNVs and population variability A PubMed search was undertaken (March 2018) using the search terms "CDKN1C", "human" and "growth", or "IMAGe syndrome". Reports focusing on growth restriction phenotypes associated with single nucleotide variants were considered. Population variation in CDKN1C was assessed using the gnomAD browser (http://gnomad.broadinstitute.org; accessed April 2018) (Lek et al., 2016) . Protein conservancy analysis was performed using ClustalW in Jalview (Waterhouse et al., 2009) .
Analysis of CDKN1C expression RNA-Seq data for CDKN1C expression was obtained with specific permission from the Human Protein Atlas (Human Protein Atlas available from www.proteinatlas.org) and re-drawn in R (version 3.4.2) (Uhlen et al., 2015) .
Study cohorts
The following growth restriction cohorts were included in this study: 1) SRS (n=58) (isolated, non-familial) diagnosed on consensus criteria and where maternal uniparental disomy or H19/IGF2:IG-DMR (also known as ICR1 or IC) hypomethylation had been excluded (Wakeling et al., 2017) ; 2) FGR (n=26) (isolated, non-familial) defined as birth weight less than the 3rd centile, as part of the Baby Bio Bank cohort (UCL-GOS Institute of Child Health & St Mary's Imperial College London) (Leon et al., 2016) . Additional analysis was undertaken in DNA from 3) products of conception (POC) (n=21) where there had been a spontaneous loss of pregnancy and 4) mothers who had a history of recurrent miscarriages (n=71) (at least three miscarriages) where an underlying cause was not known (Baby Bio Bank). An overview of these cohorts is provided in Table 1 . Sequencing libraries were prepared using 50ng of genomic DNA following the manufacturer's protocol (HaloPlex HS Target Enrichment System for Illumina Sequencing version C1 from December 2016) and as described in principle previously (Guran et al., 2016) . This was followed by 2 x 100bp or 2 x 149bp paired end sequencing to a median read depth of 300x on a NextSeq sequencer (Illumina Inc.). The bcl files were converted to fastq files using manufacturers recommended guidelines and were then analysed in SureCall software (version 4.0.1.46 (Agilent Technologies) using the HaloPlex Default Method or custom settings (minimum number of read pairs per barcode =1). Samples with a minimum read depth less than 4 at any single nucleotide position were excluded.
Results
Single nucleotide variants in CDKN1C
Review of available data revealed six publications describing isolated individuals (7) or families (4) et al., 2012; Bodian et al., 2014; Brioude et al., 2013; Hamajima et al., 2013; Kato et al., 2014; Kerns et al., 2014) . These codons are highly conserved amongst species (Figure 2) . Multiple individuals from different ancestral backgrounds were found to have p.Asp274Asn or p.Lys278Glu changes.
Variants in CDKN1C associated with familial Silver-Russell syndrome or growth restriction but normal adrenal function were found towards the carboxyl-terminal region of this "hot-spot" domain (p.Arg279Leu, p.Arg281Ile) (Figure 1 ).
Analysis of population data from the gnomAD browser showed a complete absence of variants in the key codons listed. Very rare heterozygous SNVs were found that are predicted to cause p.Ala277Val (11:2905355G>A;1 in 107288 alleles) and p.Ala283Val (11:2905337G>A; rs776541692; 1 in 30726 alleles) changes. Of note, these codons are two of the lesser-conserved amino acids within this "hot-spot" region ( Figure 2 ).
Expression of CDKN1C in human tissue
RNA-Seq analysis of CDKN1C in a panel of human tissues showed highest expression in the placenta (Figure 3 ; Human Protein Atlas data, https://www.proteinatlas.org/ ENSG00000129757-CDKN1C/tissue), with strong expression also in adipose tissue, ovary, adrenal, endometrium and kidney. Immunohistochemistry in the Human Protein Atlas repository shows strong staining in the nuclei of both decidual and trophoblastic cells (https://www.proteinatlas.org/ENSG00000129757-CDKN1C/ tissue/placenta).
Analysis of CDKN1C variants in growth restriction
Analysis of the PCNA-binding domain of CDKN1C by Sanger sequencing in a cohort of 58 children with isolated (nonfamilial) Silver-Russell syndrome did not reveal any pathogenic variants. Sequencing data for exon 2 is shown in Supplementary Data 1 (Achermann, 2018).
A next-generation sequencing approach of CDKN1C in children with IUGR/FGR (n=26), products of conception (n=21), and mothers with a history of recurrent miscarriage (n=71) also did not reveal pathogenic variants in this region (Table 1) . Details of coverage for each sample/cohort and each nucleotide is shown in Supplementary Data 2-7 (Achermann, 2018).
Discussion
CDKN1C is now well-established as a key regulator of cell cycle and growth through G1 phase cell cycle arrest. Although loss-of-function of CDKN1C is known to cause macrosomia as part of Beckwith-Wiedemann Syndrome, it is only in the past six years that "gain-of-function" variants in CDKN1C have been shown to cause growth restriction and IMAGe syndrome. These findings demonstrate clearly how opposite effects in protein function can have opposite phenotypes (Arboleda et al., 2012; Eggermann et al., 2014) . Sometimes these features affect not just growth but also endocrine systems (e.g. adrenal tumours (BWS)/adrenal hypoplasia (IMAGe); congenital hyperinsulinism (BWS)/diabetes mellitus (one family with growth restriction)).
Review of published literature confirms that CDKN1C SNVs associated with IMAGe syndrome or growth restriction are all located within a "hot-spot" of the PCNA-binding domain of the protein. The exact function of this region is not clear, and the crystal structure of this region of CDKN1C has not yet been solved. Studies to date suggest pathogenic variants may increase protein stability or reduce the rate of degradation, thereby enhancing the negative effects of CDKN1C on cell cycle progression (Borges et al., 2015; Hamajima et al., 2013) . The very localised nature of these variants clearly demonstrates a key role for this region in CDKN1C function.
CDKN1C is strongly expressed in fetal adrenal development as shown by qPCR and immunohistochemistry (Arboleda et al., 2012) , by microarray (Del Valle et al., 2017) , and RNA-Seq (unpublished). Furthermore, analysis of RNA-Seq data from the Human Protein Atlas shows marked expression in the placenta (Figure 3 ). Immunohistochemistry shows strong nuclear staining in both decidual and trophoblastic cells. Therefore, gain-of-function of CDKN1C in the developing placenta could have a significant contribution to the growth restriction phenotype.
Further evidence for a potential role for CDKN1C in fetal growth restriction phenotypes has emerged with reports of CDKN1C variants in familial growth restriction and familial SRS (Brioude et al., 2013; Kerns et al., 2014) . Several features of IMAGe syndrome and SRS overlap, such as bi-frontal bossing and relative micrognathia. To date these children have not shown evidence of adrenal insufficiency. Whilst a lack of adrenal features could be due to underlying mosaicism or a somatic "rescue" event, as recently reported for variants in SAMD9 in the related condition MIRAGE syndrome (Buonocore et al., 2017; Narumi et al., 2016) , the fact that several individuals in a family with the same CDKN1C SNV were affected provides strong evidence that the primary genomic event is influencing the phenotype rather than a rescue mechanism. Of note, review of the two SNVs associated with FGR and normal adrenal function reveals that they affect amino acids at the C-terminal region of the hotspot. In one family a charged arginine at codon 279 is replaced by a non-polar leucine, whereas a proline at this position is found in classic IMAGe syndrome. In another family, the arginine at position 281 is replaced by a non-polar isoleucine. In some situations, variants in amino-acids flanking critical motifs can be associated with milder phenotypes (Kyriakakis et al., 2017) .
Despite these findings, we did not identify any CDKN1C variants in children with isolated (non-familial) SRS or IUGR/ FGR. These results are similar to data from Brioude et al. who only reported a CDKN1C variant in familial SRS and did not find variants in 68 children with an isolated condition (Brioude et al., 2013) . Whilst this does not exclude CDKN1C as a potential cause of isolated or sporadic SRS/FGR, it does suggest that it is not a common cause.
Identification of such strong expression of CDKN1C in the placenta lead us to consider whether gain-of-function/increased stability of CDKN1C could be associated with loss of pregnancy or recurrent miscarriage. This hypothesis was supported further by recent studies linking placental genes to pregnancy loss (Perez-Garcia et al., 2018) ; a potential role for placental CDKN1C expression in fetal growth and regulation by oestrogen (Chen et al., 2018; Gou et al., 2017; López-Abad et al., 2016; Unek et al., 2014) ; and the fact that paternal imprinting of the gene means that a pool of deleterious variants could be present in the population and cause pregnancy loss (together with live births) in women who carry this variant and inherit it from their father.
Analysis was therefore undertaken in a cohort of mothers who had recurrent miscarriages (often together with live birth(s)) and also from products of conception. However, no variants were found in the PCNA binding domain of CDKN1C in these cohorts.
This work has several limitations. Although 176 total individuals were studied, each sub group is still relatively small and rare CDKN1C variants might be discovered if the sample size is increased. The causes of recurrent miscarriage and fetal growth restriction are clearly diverse and can be influenced by many factors, and regulatory regions or enhancers (Perez-Garcia et al., 2018; Rai & Regan, 2006; Stalman et al., 2018; Wakeling et al., 2017) . Nevertheless, this study does highlight the role of the key region of CDKN1C in human fetal growth restriction phenotypes, and starts to address the potential role of single gene growth restriction phenotypes in more common obstetric and fetal conditions. In this report Suntharalingham and colleagues investigate the extent to which variations in a known negative regulator of cell growth (CDKN1C) may be involved in isolated growth restriction or recurrent pregnancy loss.
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They approach this in several ways: Through analysis of published literature Through analysis of CDKN1C expression in multiple tissues using available RNA-seq data Targeted sequencing in a number of patient populations. As a result of the literature search, they conclude that reported variants are located in the PCNA-binding domain of CDKN1C and therefore focus on this for their sequencing analysis. The analysis of available RNA-seq data suggests that the gene is highly expressed in placenta, suggesting it may have a role in pregnancy maintenance. Sequencing analysis revealed no pathogenic variants in the targeted region of CDKN1C suggesting this is an uncommon cause of fetal growth restriction or recurrent pregnancy loss.
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